Smith & Nephew (LSE:SN.) FFO


LSE:SN. Smith & Nephew PLC LSE:SN.
84 GF Score
Price £10.91
GF Value £11.87
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Smith & Nephew FFO?

FFO (Funds from operations) only applies to REITs.

LSE:SN.
84GF Score
Smith & Nephew PLC LSE:SN.
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Smith & Nephew (LSE:SN.) Overvalued in 2026?

Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued. The current stock price of £10.91 is trading 8.1% below its estimated GF Value™ of £11.87. GuruFocus considers Smith & Nephew to be Fairly Valued.

Key valuation signals for LSE:SN.:

  • FFO:
  • GF Value™: £11.87 vs. price of £10.91 (8.1% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the LSE:SN. stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Smith & Nephew Business Description

Address Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, GBR, WD18 8YE
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
84GF Score

Get the complete analysis for LSE:SN.

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£10.91
Price
£11.87
GF Value